Jonathan D. Marmur, MD, FACC

Feature

Direct Versus Indirect Thrombin Inhibition in Percutaneous Coronary Intervention (Part I)

08/01/2008

Heparin Heparin has been used to prevent intravascular thrombosis and clotting on the surface of equipment used during percutaneous coronary interventions (PCI) since Andreas Gruentzig performed the first angioplasty.1 In fact, the...

Heparin Heparin has been used...

08/01/2008

Journal of Invasive Cardiology

Original Contribution

The Nature and Pattern of Coronary Stent Recalls

09/06/2014

Jonathan D. Marmur , MD, FACC;

Sanjay Kumar , MD, BSc, MBBS, MRCP;

Antony L. Innasimuthu , MD;

In rare cases stents have been recalled by their manufacturers due to unanticipated problems. This study examined the extent and pattern of these stent recalls.

In rare cases stents have been...

09/06/2014

Journal of Invasive Cardiology

Feature

Direct Versus Indirect Thrombin Inhibition in Percutaneous Coronary Intervention (Part II)

08/01/2008

Jonathan D. Marmur , MD, FACC;

Continued from previous page Randomized trials. A retrospective analysis of randomized studies supports the findings of the case-control studies. In 1,863 heparin-treated patients, there was an inverse relation between the ACT values...

Continued from previous...

08/01/2008

Journal of Invasive Cardiology

Clinical Images

Coronary Air Embolization in the Left Coronary Artery

08/01/2008

Spyros Kokolis , MD;

Alan Feit , MD;

Jonathan D. Marmur , MD, FACC;

Coronary air embolism is a recognized complication of cardiac catheterization occurring in 0.1–0.3% of cases.1 Sequelae range from various clinically-insignificant events to an acute coronary syndrome and death.2 The possible mechanisms of...

Coronary air embolism is a...

08/01/2008

Journal of Invasive Cardiology

Original Contribution

High-Dose Tirofiban Administered as Bolus-Only during
Percutaneous Coronary Intervention

08/01/2008

Nagarathna Manjappa , MD;

Jonathan D. Marmur , MD, FACC;

Erdal Cavusoglu , MD;

Shyam Poludasu , MD;

Ajay Agarwal , MD;

Inhibition of platelet glycoprotein IIb/IIIa receptors during percutaneous coronary intervention (PCI) using tirofiban, eptifibatide and abciximab has been associated with improved outcomes.1 The only head-to-head comparison to these agents...

Inhibition of platelet...

08/01/2008

Journal of Invasive Cardiology

Original Contribution

Impact of Gender on In-Hospital Percutaneous Coronary Interventional Outcomes in African-Americans

08/01/2008

Jonathan D. Marmur , MD, FACC;

Erdal Cavusoglu , MD;

Luther T. Clark , MD;

Shyam Poludasu , MD;

Multiple studies have demonstrated that women are at increased risk for in-hospital mortality, stroke, vascular complications, repeat revascularization, and same-admission coronary artery bypass graft surgery (CABG) after percutaneous...

Multiple studies have...

08/01/2008

Journal of Invasive Cardiology

Original Contribution

Bolus-Only Platelet Glycoprotein IIb/IIIa Inhibition During Percutaneous Coronary Intervention

08/01/2008

Reuven Lapin , PA-C, PA;

Shyam Poludasu , MD;

Jonathan D. Marmur , MD, FACC;

Erdal Cavusoglu , MD;

Pompeiu Vladutiu , MD;

Ajay Agarwal , MD;

Alan Feit , MD;

Several large randomized clinical trials and meta-analyses have shown that inhibition of platelet aggregation with platelet glycoprotein IIb/IIIa inhibitors (GPI) improves outcomes in patients presenting with acute coronary syndromes and in...

Several large randomized...

08/01/2008

Journal of Invasive Cardiology

Original Contribution

Effects of Alcoholism on Coronary Artery Disease and Left Ventricular Dysfunction in Male Veterans

08/01/2008

Spyros Kokolis , MD;

Luther T. Clark , MD;

Jonathan D. Marmur , MD, FACC;

John Kassotis , MD;

Erdal Cavusoglu , MD;

Rodamanthos Kokolis , MD;

Reuven Lapin , PA-C, PA;

Sheldon Breitbart , MD;

Jason M. Lazar , MD;

Light-to-moderate alcohol consumption has been associated with a decreased risk of ischemic cardiac events and stroke.1 The cardioprotective effects of alcohol have been attributed to favorable lipid changes, including lower LDL, increased...

Light-to-moderate alcohol...

08/01/2008

Journal of Invasive Cardiology

Original Contribution

A Novel Point-of-Care Assay for the Monitoring of Low-Molecular Weight Heparins in the Cardiac Catheterization Laboratory

09/15/2008

Jonathan D. Marmur , MD, FACC;

Manish Lakhani , MD;

Erdal Cavusoglu , MD;

Soumaya El Rouby , MD;

ABSTRACT: Background. We designed a study to compare the novel point-of-care assay Hemonox clotting time (Hemonox-CT) with the activated clotting time (ACT) and anti-Xa activity to monitor the anticoagulation effects of enoxaparin and...

ABSTRACT: Background. We...

09/15/2008

Journal of Invasive Cardiology

Activated Clotting Time (ACT)-Guided Intravenous Dalteparin Dosing during Percutaneous Coronary Intervention

08/01/2008

Alan Feit , MD;

Shyam Poludasu , MD;

Jonathan D. Marmur , MD, FACC;

Erdal Cavusoglu , MD;

Venkata R. Battala , MBBS;

The superiority of low-molecular weight heparin (LMWH) over unfractionated heparin (UFH) in the management of acute coronary syndrome (ACS) patients was demonstrated in the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary...

The superiority of low-molecular...

08/01/2008

Journal of Invasive Cardiology